New York - Even as biologic therapies become available, there will still be a place for acitretin, methotrexate and cyclosporin-based treatment protocols, according to Mark Lebwohl, M.D.
The Weekly Roundup: April 29-May 3
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Alpha Tau to Conduct Trial of Alpha DaRT Technology In Patients With Recurrent Squamous Cell Carcinoma
ReV Up Your Vitiligo Treatment Strategies
QUIZ RECAP: Test Your Knowledge of Rosacea Research and Innovations
Reviewing Concerns For Mental Health and Well-Being in Dermatologic Conditions